Neonatal outcomes following in utero exposure to methadone or buprenorphine: A National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009

Drug and Alcohol Dependence

Volumn 127, Issue 1-3, 2013, Pages 200-206

  Welle Strand, Gabrielle K ^a,b   Skurtveit, Svetlana ^a,c   Jones, Hendreé E ^d   Waal, Helge ^a   Bakstad, Brittelise ^b   Bjarkø, Lisa ^e   Ravndal, Edle ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Norwegian Directorate of Health   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d RTI INTERNATIONAL   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Buprenorphine; Methadone; Neonatal outcomes; Norway; Pregnancy

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; ILLICIT DRUG; METHADONE; OPIATE;

ALCOHOL CONSUMPTION; ARTICLE; BODY HEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GESTATIONAL AGE; HEAD CIRCUMFERENCE; HIGH BIRTH WEIGHT; HUMAN; INCIDENCE; MAINTENANCE THERAPY; NATIONAL CLINICAL COHORT STUDY; NEWBORN; NORWAY; PREGNANCY; PREGNANT WOMAN; PRENATAL EXPOSURE; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; TREATMENT DURATION; TREND STUDY; TYPES OF STUDY; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; NORWAY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

NICOTIANA TABACUM;

EID: 84870869597     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.07.001     Document Type: Article

References (39)

1. Bakstad B., Sarfi M., Welle-Strand G.K., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur. Addict. Res. 2009, 15:128-134.
2. Cleary B.J., Donnelly J., Strawbridge J., Gallagher P.J., Fahey T., Clarke M., Murphy D.J. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. Addiction 2010, 105:2071-2084.
3. Doberczak T.M., Thornton J.C., Bernstein J., Kandall S.R. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am. J. Dis. Child. 1987, 141:1163-1167.
4. Draper E.S., Rankin J., Tonks A.M., Abrams K.R., Field D.J., Clarke M., Kurinczuk J.J. Recreational drug use: a major risk factor for gastroschisis?. Am. J. Epidemiol. 2008, 167:485-491.
5. Finnegan L., Winklbaur B., Fischer G., Olofsson M., Welle-Strand G.K. New approaches in the treatment of opioid dependency during pregnancy. Heroin Addict. Relat. Clin. Probl. 2009, 11:47-57.
6. Finnegan L.P., Connaughton J.F., Kron R.E., Emich J.P. Neonatal abstinence syndrome: assessment and management. Addict. Dis. 1975, 2:141-158.
7. Finnegan L.P., Reeser D.S., Connaughton J.F. The effects of maternal drug dependence on neonatal mortality. Drug Alcohol Depend. 1977, 2:131-140.
8. Fischer G., Eder H., Jagsch R., Lennkh A., Habeier A., Aschauer H., Kasper S. Maintenance therapy with synthetic opioids within a multidisciplinary program - a stabilizing necessity for pregnant opioid dependent women. Arch. Womens Ment. Health 1998, 1-8.
9. Fischer G., Etzersdorfer P., Eder H., Jagsch R., Langer M., Weninger M. Buprenorphine maintenance in pregnant opiate addicts. Eur. Addict. Res. 1998, 4(Suppl. 1):32-36.
10. Fischer G., Johnson R.E., Eder H., Jagsch R., Peternell A., Weninger M., Langer M., Aschauer H.N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 2000, 95:239-244.
11. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006, 101:275-281.
12. Hulse G.K., Milne E., English D.R., Holman C.D. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997, 92:1571-1579.
13. Hytinantti T., Kahila H., Renlund M., Jarvenpaa A.L., Halmesmaki E., Kivitie-Kallio S. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr. 2008, 97:1040-1044.
14. Jansson L.M., Di Pietro J.A., Elko A., Williams E.L., Milio L., Velez M. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. Drug Alcohol Depend. 2012, 122:213-219.
15. Jansson L.M., Svikis D.S., Velez M., Fitzgerald E., Jones H.E. The impact of managed care on drug-dependent pregnant and postpartum women and their children. Subst. Use Misuse 2007, 42:961-974.
16. Johnson R.E., Jones H.E., Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003, 70:87-101.
17. Johnson R.E., Jones H.E., Jasinski D.R., Svikis D.S., Haug N.A., Jansson L.M., Kissin W.B., Alpan G., Lantz M.E., Cone E.J., Wilkins D.G., Golden A.S., Huggins G.R., Lester B.M. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001, 63:97-103.
18. Jones H.E., Johnson R.E., Jasinski D.R., O'Grady K.E., Chisholm C.A., Choo R.E., Crocetti M., Dudas R., Harrow C., Huestis M.A., Jansson L.M., Lantz M., Lester B.M., Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005, 79:1-10.
19. Jones H.E., Kaltenbach K., Heil S.H., Stine S.M., Coyle M.G., Arria A.M., O'Grady K.E., Selby P., Martin P.R., Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 2010, 363:2320-2331.
20. Jones H.E., Martin P.R., Heil S.H., Kaltenbach K., Selby P., Coyle M.G., Stine S.M., O'Grady K.E., Arria A.M., Fischer G. Treatment of opioid-dependent pregnant women: clinical and research issues. J. Subst. Abuse Treat. 2008, 35:245-259.
21. Jones H.E., Suess P., Jasinski D.R., Johnson R.E. Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study. Am. J. Addict. 2006, 15:61-70.
22. Kahila H., Saisto T., Kivitie-Kallio S., Haukkamaa M., Halmesmaki E. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet. Gynecol. Scand. 2007, 86:185-190.
23. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008, 96:69-78.
24. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet. Gynecol. Clin. North Am. 1998, 25:139-151.
25. Kandall S.R., Albin S., Gartner L.M., Lee K.S., Eidelman A., Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum. Dev. 1977, 1:159-169.
26. Lacroix I., Berrebi A., Garipuy D., Schmitt L., Hammou Y., Chaumerliac C., Lapeyre-Mestre M., Montastruc J.L., Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur. J. Clin. Pharmacol. 2011, 67:1053-1059.
27. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend. 2006, 82:250-257.
28. Lipsitz P.J. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin. Pediatr. 1975, 14:592-594.
29. Liu A.J., Jones M.P., Murray H., Cook C.M., Nanan R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust. N. Z. J. Obstet. Gynaecol. 2010, 50:253-258.
30. Luty J., Nikolaou V., Bearn J. Is opiate detoxification unsafe in pregnancy? [see comment]. J. Subst. Abuse Treat. 2003, 24:363-367.
31. McCarthy J.J. Intrauterine abstinence syndrome (IAS) during buprenorphine inductions and methadone tapers: can we assure the safety of the fetus?. J. Matern. Fetal Neonatal Med. 2012, 25:109-112.
32. Mitchell L.E., Adzick N.S., Melchionne J., Pasquariello P.S., Sutton L.N., Whitehead A.S. Spina bifida. Lancet 2004, 364:1885-1895.
33. Newman R.G., Bashkow S., Calko D. Results of 313 consecutive live births of infants delivered to patients in the New York City Methadone Maintenance Treatment Program. Am. J. Obstet. Gynecol. 1975, 121:233-237.
34. Seligman N.S., Salva N., Hayes E.J., Dysart K.C., Pequignot E.C., Baxter J.K. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am. J. Obstet. Gynecol. 2008, 199:396-397.
35. Simmat-Durand L., Lejeune C., Gourarier L. Pregnancy under high-dose buprenorphine. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009, 142:119-123.
36. Welle-Strand G.K. Questionnaire for Pregnancy/birth in Medication Assisited Rehabilitation (MAR) 1999, Centre for Medication Assisted Rehabilitation (MAR), Oslo.
37. Welle-Strand G.K., Waal H. Guideline for Medication Assisted Rehabilitation in Pregnancy 2001, Centre for Medication Assisted Rehabilitation (MAR), Oslo.
38. WHO Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence 2009, World Health Organisation, Geneva.
39. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008, 103:1429-1440.